Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma

Table 1 Association of PRL-3 expression with clinicopathological parameters in gastric cancer

Variables	Patients (n)	Expression of PRL-3		χ²	P
Variables	Patients (n)	Negative (%)	Positive (%)	χ²	P
Age
<60	93	77 (82.8)	16 (17.2)	0.540	0.463
≥60	103	81 (78.6)	22 (21.4)
Sex
Male	146	123 (84.2)	23 (15.8)	4.837	0.128
Female	50	35 (70.0)	15 (30.0)
Diagnosis*
GC	177	145 (81.9)	32 (18.1)	2.001	0.217
GEC	19	13 (68.4)	6 (31.6)
TNM stage
I	33	29 (87.9)	4 (12.1)	6.170	0.100
II	50	44 (88.0)	6 (12.0)
III	92	71 (77.2)	21 (22.8)
IV	21	14 (66.7)	7 (33.3)
Tumor invasion
T1	20	17 (85.0)	3 (15.0)	1.654	0.659
T2	27	23 (85.2)	4 (14.8)
T3	78	64 (82.1)	14 (17.9)
T4	71	54 (76.1)	17 (23.9)
Lymph node metastasis
Negative	59	52 (88.1)	7 (11.9)	12.298	0.006
N1	40	36 (90.0)	4 (10.0)
N2	34	28 (82.4)	6 (17.6)
N3	63	42 (66.7)	21 (33.3)
Metastasis
Negative	175	144 (82.3)	31 (17.7)	2.927	0.138
Positive	21	14 (66.7)	7 (33.3)
Differentiation
Well	13	12 (92.3)	1 (7.7)	1.781	0.410
Moderately	89	69 (77.5)	20 (22.5)
Poor	94	77 (81.9)	17 (18.1)
Histology
Adenocarcinoma	154	126 (81.8)	28 (18.2)	0.669	0.413
Others	42	32 (76.2)	10 (23.8)
Vascular invasion
Negative	123	109 (88.6)	14 (11.4)	13.543	0.000
Positive	73	49 (67.1)	24 (32.9)

*GC: Gastric cancer; GEC: Gastroesophageal Cancer. Statistical analysis showed significant positive associations of PRL-3 expression with lymph node involvement and vascular invasion.

ISSN: 1479-5876